Predictive Factors for Efficacy of Oral Tacrolimus Induction Therapy in Moderate to Severe Ulcerative Colitis Patients: Large Multicenter Retrospective Cohort Study.

Autor:	Oshima N; Inflammatory Bowel Disease Center, Shimane University Hospital, 89-1, Enya-cho, Izumo, Shimane 693-8501, Japan.; Department of Internal Medicine II, Shimane University Faculty of Medicine, 89-1, Enya-cho, Izumo, Shimane 693-8501, Japan., Hiraoka S; Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Hayashi R; Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan., Takahashi S; Department of Gastroenterology, Kagawa Prefectural Central Hospital, Kagawa, Japan., Ishii M; General Internal Medicine 2, General Medical Center, Kawasaki Medical School, Okayama, Japan., Hashimoto S; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan., Yashima K; Division of Gastroenterology and Nephrology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Tottori, Japan., Igawa S; Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Inokuchi T; Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Ueno Y; Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan., Inaba T; Department of Gastroenterology, Kagawa Prefectural Central Hospital, Kagawa, Japan., Matsumoto H; Division of Gastroenterology, Kawasaki Medical School, Okayama, Japan., Kawashima K; Inflammatory Bowel Disease Center, Shimane University Hospital, 89-1, Enya-cho, Izumo, Shimane 693-8501, Japan.; Department of Internal Medicine II, Shimane University Faculty of Medicine, 89-1, Enya-cho, Izumo, Shimane 693-8501, Japan., Takami T; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan., Isomoto H; Division of Gastroenterology and Nephrology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Tottori, Japan., Shiotani A; Division of Gastroenterology, Kawasaki Medical School, Okayama, Japan., Tanaka S; Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan., Ishihara S; Inflammatory Bowel Disease Center, Shimane University Hospital, 89-1, Enya-cho, Izumo, Shimane 693-8501, Japan.; Department of Internal Medicine II, Shimane University Faculty of Medicine, 89-1, Enya-cho, Izumo, Shimane 693-8501, Japan.
Jazyk:	angličtina
Zdroj:	Inflammatory bowel diseases [Inflamm Bowel Dis] 2024 Jul 03; Vol. 30 (7), pp. 1087-1093.
DOI:	10.1093/ibd/izad150
Abstrakt:	Background: Tacrolimus (TAC), a calcineurin inhibitor, is used for remission induction therapy in patients with moderate to severe ulcerative colitis (UC), with short-term efficacy and related predictive factors shown in previous cohort studies. However, most studies reported data for only a limited number of patients enrolled from a single center. We performed a large multicenter retrospective cohort study to identify factors related to prediction of clinical remission in UC patients treated with oral TAC. Methods: The medical records of patients with moderate to severe UC treated with oral TAC as induction therapy at 7 institutions between April 2009 and March 2017 were retrospectively reviewed. Results: A total of 216 patients who received TAC for induction were analyzed, of whom 123 (56.9%) showed clinical remission at week 12. Logistic regression analysis indicated that previous or current use of antitumor necrosis factor (TNF)-α antibodies (odds ratio [OR], 0.259; P = .006), and concomitant treatment with 5-aminosalicylate (5-ASA) at the baseline (OR, 0.268; P = .005) were independent predictive factors correlated with failure of clinical remission, whereas higher levels of C-reactive protein (OR, 1.124; P = .014) predicted achievement of clinical remission. Conclusions: Results of this multicenter study clearly indicate the efficacy of TAC induction therapy for patients with moderate to severe UC. Notably, previous or current use of anti-TNF-α antibodies was associated with poor achievement of clinical remission by week 12. (© The Author(s) 2023. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu